A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) (LIN-MD-62)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02559570
Recruitment Status : Completed
First Posted : September 24, 2015
Last Update Posted : June 12, 2018
Ironwood Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Forest Laboratories

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : April 20, 2018
  Actual Study Completion Date : May 29, 2018